secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2026-05-26T20:48:01+00:00
Accession:  0001193125-26-239535
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics annual meeting elects two Class II directors, ratifies auditor
--------------------------------------------------------------------------------

- J. Matthew Singleton elected with 28.6M votes for; S. Kathryn Rouan with 22.0M for.
- Ratification of CBIZ CPAs as independent auditor for FY 2026 approved (78.4M for, 1.2M against).
- Advisory vote on named executive officer compensation passed (30.0M for, 12.8M against).
- Quorum achieved with 80.1M shares (69.1% of outstanding) represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526239535/0001193125-26-239535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526239535/vktx-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-239535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer